Not-for-profit preclinical CRO Lovelace Biomedical born

A new contract research org, which has been named Lovelace Biomedical by its parent co, launched this week as it seeks new biotech and pharma partners for early-stage drug work.

The Albuquerque, NM-based CRO aims to offer a range of services to potential clients, including toxicology and pharmacology, as well as helping advance preclinical work of compounds and new tech.

The company says it has services and expertise “spanning the fields of respiratory disease, infectious disease, gene therapy, neuroscience, alternative tobacco products and medical countermeasures, as well as drug discovery and others.”

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

It comes out of the Lovelace family of companies, and says that as a non-profit, “we are beholden to science--and not shareholders. We invest generously in basic science and cutting-edge technologies so that we can help you accomplish your research objectives, no matter how complex.”

“The Lovelace family of companies has a rich history in scientific innovation--from pioneering aviation medicine and work with NASA, to ground-breaking research in respiratory illnesses and infectious diseases,” said Robert W. Rubin, Ph.D., president and CEO of the Lovelace Respiratory Research Institute and associated companies.

“Today we carry this tradition of scientific excellence through our collaborations with biotechnology and pharmaceutical companies that seek to improve lives by treating devastating diseases and disorders. Our expertise in preclinical research can help these companies answer difficult questions about their therapeutic programs and find the right path forward toward clinical investigation and regulatory approval.”

The CRO works out of a bio-secure facility on 100 acres of land with 300,000 square feet of lab space. In addition to toxicology, Lovelace says it also has expertise with a “wide-variety of large and small animal pharmacology models,” as well as more than 10,000 square feet of ABSL3-enhanced lab space.

Suggested Articles

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.